Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer in the UK

被引：0

作者：

Karnon, J

Delea, TE

Papo, NL

Barghout, V

Thomas, SK

Johnston, SR

机构：

[1] Univ Sheffield, Sheffield, S Yorkshire, England

[2] Policy Anal Inc, Brookline, MA USA

[3] Novartis Pharmaceut UK Ltd, Camberley, England

[4] Novartis Pharmaceut Corp, Florham Pk, NJ USA

[5] Novartis Pharmaceut Corp, E Hanover, NJ USA

[6] Royal Marsden Hosp, London SW3 6JJ, England

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)67270-1

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A43 / A43

页数：1

共 50 条

[1] Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective
Karnon, J
Delea, TE
Barghout, V
Thomas, SK
Papo, NL
Johnston, SRD
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S104 - S104
[2] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer.
Delea, T. E.
Karnon, J.
Sofrygin, O.
Thomas, S. K.
Barghout, V
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S116 - S117
[3] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
Delea, Thomas E.
El-Ouagari, Khalid
Karnon, Jonathan
Sofrygin, Oleg
BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (03) : 375 - 387
[4] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a Canadian perspective
Delea, Thomas E.
El Ouagari, Khalid
Karnon, Jon
Sofrygin, Oleg
Barghout, Victoria
ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
[5] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
Thomas E. Delea
Khalid El-Ouagari
Jonathan Karnon
Oleg Sofrygin
Breast Cancer Research and Treatment, 2008, 108 : 375 - 387
[6] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective
Delea, TE
Karnon, J
Thomas, SK
Barghout, V
Papo, NL
Johnston, SRD
BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S102 - S102
[7] Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer:: the Belgian perspective
Kannon, J.
Berliere, M.
Depypere, H.
Dirix, L.
Jerusalem, G.
Neven, P.
Pandaens, R.
Lecomte, P.
BREAST, 2007, 16 : S64 - S65
[8] Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer
Delea, Thomas E.
Karnon, Jon
Sofrygin, Oleg
Thomas, Simu K.
Papo, Natalie L.
Barghout, Victoria
CLINICAL BREAST CANCER, 2007, 7 (08) : 608 - 618
[9] Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy for postmenopausal women with early hormone-receptor positive breast cancer - an evaluation of the ATAC-trial.
Lundkvist, J.
Paulsson, T.
Borgstrom, F.
Kasteng, F.
Sobocki, P.
Lidgren, M.
Henriksson, R.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S229 - S229
[10] Comparison of the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor positive (HR+) postmenopausal women: The UK perspective
Karnon, Jonathan
Delea, Thomas
Papo, Natalie L.
Barghout, Victoria
ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107

← 1 2 3 4 5 →